2-trifluoromethyl-5-methyl-4H-3,1-benzoxazin-4-one | 106324-52-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 2-trifluoromethyl-5-methyl-4H-3,1-benzoxazin-4-one
• 英文别名: 2-trifluoromethyl-5-methyl-benzoxazinone；5-methyl-2-trifluoromethyl-4H-3,1-benzoxazin-4-one；2-Trifluoromethyl-5-methyl-4H-3,1-benzoxazin-4-one；5-methyl-2-(trifluoromethyl)-3,1-benzoxazin-4-one
• CAS: 106324-52-1
• 化学式: C₁₀H₆F₃NO₂
• 分子量: 229.158
• InChiKey: NMGDXCBZTVNKBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  258.8±50.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-trifluoromethyl-5-methyl-4H-3,1-benzoxazin-4-one 在 ammonium acetate 、 肼 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 11.0h， 生成
  参考文献：
  名称：

  The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of In vitro and In vivo studies

  摘要：

  We have developed novel orally active quinazoline analogues as inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. Among the derivatives prepared, 1-[2-(2-thienyl)quinazolin-4-ylamino]-3-methyl-3-pyrroline-2,5-dione (10) showed significant activity in an adjuvant-induced arthritis rat model by reducing the swelling by 65% in the non-injected foot. The synthesis, structure-activity relationship, and in vivo activity are described. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.047
• 作为产物：
  描述：

  2-甲基-6-[(2,2,2-三氟乙酰)氨基]苯甲酸 在 乙酸酐 作用下， 反应 1.0h， 生成 2-trifluoromethyl-5-methyl-4H-3,1-benzoxazin-4-one
  参考文献：
  名称：

  The design and synthesis of novel orally active inhibitors of AP-1 and NF-κB mediated transcriptional activation. SAR of In vitro and In vivo studies

  摘要：

  We have developed novel orally active quinazoline analogues as inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. Among the derivatives prepared, 1-[2-(2-thienyl)quinazolin-4-ylamino]-3-methyl-3-pyrroline-2,5-dione (10) showed significant activity in an adjuvant-induced arthritis rat model by reducing the swelling by 65% in the non-injected foot. The synthesis, structure-activity relationship, and in vivo activity are described. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.047

文献信息

• Design, Synthesis, and Structure–Activity Relationship of Quinazolinone Derivatives as Potential Fungicides
  作者：Jing-Wen Peng、Xiao-Dan Yin、Hu Li、Kun-Yuan Ma、Zhi-Jun Zhang、Rui Zhou、Yu-Ling Wang、Guan-Fang Hu、Ying-Qian Liu

  DOI：10.1021/acs.jafc.0c05475

  日期：2021.4.28

  Plant diseases caused by phytopathogenic fungi reduce the yield and quality of crops. To develop novel antifungal agents, we designed and synthesized eight series of quinazolinone derivatives and evaluated their anti-phytopathogenic fungal activity. The bioassay results revealed that compounds KZL-15, KZL-22, 5b, 6b, 6c, 8e, and 8f exhibited remarkable antifungal activity in vitro. Especially, compound

  由植物致病真菌引起的植物病害降低了作物的产量和质量。为了开发新型的抗真菌剂，我们设计并合成了8个系列的喹唑啉酮衍生物，并评估了它们的抗植物病原性真菌活性。生物测定结果表明，化合物KZL-15，KZL-22，图5b，图6b，图6c，图8E和图8F显示出显着的抗真菌活性在体外。尤其是，化合物6c对巩膜核盘菌，Satellakis sasakii，镰刀镰刀菌（Fusarium graminearum）和尖孢镰刀菌（Fusarium oxysporum）的IC 50值（抑制浓度50％）分别为2.46、2.94、6.03和11.9μg/ mL。进一步的机制询问显示，用化合物6c处理的菌核菌中菌丝异常，细胞器受损和细胞膜通透性改变。另外，体内生物测定法表明，化合物6c在100μg/ mL浓度下对核盘菌的治疗和保护作用（分别为87.3和90.7％）可与阳性对照嘧菌酯（分别为89.5和91.2％）相媲美。这项工作验证了化合物6c的潜力
• Quinazoline analogs and related compounds and methods for treating
  申请人：Signal Pharmaceuticals, Inc.

  公开号：US05939421A1

  公开（公告）日：1999-08-17

  Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are quinazoline-containing compounds. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.

  本发明涉及具有抗炎作用的化合物，通常用于预防和/或治疗免疫炎症和自身免疫性疾病。这些化合物是喹唑啉类化合物。本发明还揭示了通过向需要的动物施用该化合物的有效量，优选地以药物组合物的形式，来预防和/或治疗炎症病况的方法。
• Aziridination of alkenes using 2-substituted-3-acetoxyamino-quinazolin-4(3H )-ones: changes in transition state geometry resulting from addition of trifluoroacetic acid or by an electron-withdrawing 2-substituent
  作者：Robert S. Atkinson、Sabri Ulukanli

  DOI：10.1039/a809703h

  日期：——

  are interpreted as supporting a change in transition state geometry from one where (Q)CO/(ester)CO overlap 7b is replaced by (Q)CN+H/(ester)CO overlap 7c (Q = quinazolinone). Aziridinations of methyl or tert-butyl acrylate using 2-trifluoromethyl-substituted 3-acetoxyaminoquinazolinones 20 and 21 take place with (Q)CN/(ester)CO overlap 22 even in the absence of TFA.

  TFA对3-乙酰氧基氨基喹唑啉酮2和10与丙烯酸甲酯和丙烯酸叔丁酯竞争反应的影响被解释为支持过渡态几何形状的变化，其中（Q）C O /（酯）C O重叠7b被（Q）C N + H /（酯）C O重叠7c取代（Q =喹唑啉酮）。即使不存在TFA，使用2-三氟甲基取代的3-乙酰氧基氨基喹唑啉酮20和21进行丙烯酸甲酯或丙烯酸叔丁酯的氮杂环化反应也具有（Q）C N /（酯）C O重叠22。
• [EN] QUINAZOLINE ANALOGS AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS<br/>[FR] ANALOGUES DE QUINAZOLINE ET COMPOSES ASSOCIES ET METHODES POUR TRAITER LES TROUBLES INFLAMMATOIRES
  申请人：SIGNAL PHARMACEUTICALS, INC.

  公开号：WO1999001441A1

  公开（公告）日：1999-01-14

  (EN) Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are quinazoline-containing compounds. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.(FR) L'invention concerne des composés utiles de manière générale comme agents anti-inflammatoires et plus spécifiquement comme agents préventifs et/ou thérapeutiques pour les maladies immuno-inflammatoires et auto-immunes. Ces composés contiennent de la quinazoline. L'invention concerne également de méthodes pour prévenir et/ou traiter les états inflammatoires en administrant à un animal nécessitant un tel traitement une quantité efficace d'un des composés décrits, de préférence sous forme d'une composition pharmaceutique.

  该发明涉及一种具有抗炎作用的化合物，可用于预防和/或治疗免疫炎症和自身免疫疾病。这些化合物含有喹唑啉。本发明还揭示了通过向需要治疗的动物施用本发明的化合物的有效量，尤其是以药物组成物的形式，以预防和/或治疗炎症状况的方法。
• US4363651A
  申请人：——

  公开号：US4363651A

  公开（公告）日：1982-12-14